Imaging Quantification of Inflammation (IQI)
Uveitis1. Perform observational study utilizing real-time quantification of ocular inflammation to determine minimal important change. Prospective use of changes in imaging quantification of inflammation (IQI) scores in determining treatment decisions both utilizing novel FA viewer software.
Ustekinumab for Active Sight-Threatening Uveitis
UveitisBackground: - Uveitis is an eye inflammation that can cause vision loss. It is treated with eye drops, drugs and sometimes surgery. In some people, treatment may not prevent vision loss. A type of white blood cells called T-cells often have a role in causing uveitis. In some cases of uveitis, T-cells attack the eye and cause inflammation. A drug called ustekinumab reduces inflammation from these T-cells. Researchers want to see if ustekinumab can be used to treat uveitis. Objectives: - To see if ustekinumab can be used to treat uveitis. Eligibility: - Individuals at least 18 years of age who have active uveitis that needs treatment. Design: Participants will be screened with a physical exam, eye exam, and medical history. Blood and urine samples will be taken. Participants will have at least eight clinic visits during the 64-week study period. After the first visit, visits will occur at 2, 4, and 8 weeks, and then every 12 weeks. Participants will have a ustekinumab injection at the first study visit. They will have additional doses at the second and third visits, and then every 12 weeks until 1 year after the first dose (Week 52). Treatment will be monitored with frequent blood tests and eye exams. Other standard treatments for uveitis may be given as needed. There will be a final study visit 3 months after the last injection.
Study of FTY720 in Patients With Uveitis
Acute Noninfectious PosteriorIntermediate1 moreThis study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis
Safety &Efficacy of CF101 to Subjects With Uveitis
UveitisPosterior2 moreThis is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis.
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
UveitisThis study will provide patients who have completed the AIN457 Phase II and Phase III clinical trials in non-infectious uveitis continued access to treatment with AIN457 while collecting safety data and information on long term clinical use of treatment with AIN457.
Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Macular EdemaUveitisThis is a pilot study to investigate the safety and efficacy of intravitreally administered ranibizumab (Lucentis) compared to steroid injection for the treatment of macular edema due to chronic non-infectious uveitis. There is currently no FDA-approved therapy for this condition, however intravitreal injection of corticosteroids, in conjunction with oral steroids and/or immunomodulatory drug agents, has become the mainstay of therapy. Ranibizumab is a recombinant monoclonal antibody antigen-binding fragment that neutralizes the active forms of vascular endothelial growth factor (VEGF), which is believed to contribute to the etiology of inflammation and neovascularization. Ranibizumab is FDA-approved for the treatment of neovascular age-related macular degeneration.
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic...
UveitisCystoid Macular EdemaMacular edema is the most common sight threatening complication of uveitis which can lead to permanent loss of central vision. Triamcinolone acetonide ( the study drug)injection for treatment of cystoid macular edema(CME) is well established. The purpose of this study is to compare the safety and efficacy of injecting the study drug inside the eye(intravitreal injection) and behind the eye(subtenon injection)
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
UveitisPosterior1 moreRetisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA) has been shown to reduce steroid induced elevated IOP. The purpose of this study was to evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to prevent this Retisert induced elevated IOP.
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
UveitisThe multiple properties of the corticosteroids over the inflammatory response, make them first line drugs for the treatment of several ocular inflammatory disorders of different etiologies. In order to diminish the corticosteroids severe systemic adverse effects, the local administration is preferred. Iontophoresis already has been used in a successful way for the administration of corticosteroids. Clinical or histopathological injuries due to the use of transcleral CCI have not been observed. being successful the administration of methylprednisolone by means of this system in previous studies. The objective is to evaluate the tolerance, security and effectiveness of this treatment, using a new generation device.
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema...
Uveitic Macular EdemaIntraocular InflammationThe purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.